Final results from QUASAR2, a multicentre, international randomised phase III trial of capecitabine (CAP) +/- bevacizumab (BEV) in the adjuvant setting of stage II/III colorectal cancer (CRC)
R. Midgley
Final results from QUASAR2, a multicentre, international randomised phase III trial of capecitabine (CAP) +/- bevacizumab (BEV) in the adjuvant setting of stage II/III colorectal cancer (CRC)
R. Midgley